cisplatin cat Search Results


cisplatin (cat# 440-040)  (Enzo Biochem)
90
Enzo Biochem cisplatin (cat# 440-040)
( A, B ) D283-MED, MHH-Med1 and MEB-Med8A cells were treated with [20 µM] etoposide for indicated time points and levels of miR-34a (A) and Mdm2 mRNA ( B ) were assessed by real time qPCR. Results were normalised to cyclophilin A and fold changes relative to the untreated control. See also for a DMSO control. ( C ) D283-MED cells were transfected with siRNA directed to p53 or with non-specific siRNA as a negative control for 48 hours prior to etoposide treatment. The levels of miR-34a were assessed by qPCR as in (A). Data shown are the mean ± S.E.M of three independent experiments. (A–C) Kruskal-Wallis ANOVA test was performed (*indicates p<0.05). ( D – F ) Cell viability of D283-MED, MHH-Med1 and MEB-Med8A was measured by MTS assay upon treatment at indicated time points. ( D ) Etoposide [20 µM] ( E ) <t>cisplatin</t> [5 µM] ( F ) methrotrexate [5 µM]. The percentages of viable cells were relative to the untreated control. See also for a vehicle DMSO control on cell death. Data shown are the mean ± S.E.M of three independent experiments.
Cisplatin (Cat# 440 040), supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cisplatin (cat# 440-040)/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
cisplatin (cat# 440-040) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


( A, B ) D283-MED, MHH-Med1 and MEB-Med8A cells were treated with [20 µM] etoposide for indicated time points and levels of miR-34a (A) and Mdm2 mRNA ( B ) were assessed by real time qPCR. Results were normalised to cyclophilin A and fold changes relative to the untreated control. See also for a DMSO control. ( C ) D283-MED cells were transfected with siRNA directed to p53 or with non-specific siRNA as a negative control for 48 hours prior to etoposide treatment. The levels of miR-34a were assessed by qPCR as in (A). Data shown are the mean ± S.E.M of three independent experiments. (A–C) Kruskal-Wallis ANOVA test was performed (*indicates p<0.05). ( D – F ) Cell viability of D283-MED, MHH-Med1 and MEB-Med8A was measured by MTS assay upon treatment at indicated time points. ( D ) Etoposide [20 µM] ( E ) cisplatin [5 µM] ( F ) methrotrexate [5 µM]. The percentages of viable cells were relative to the untreated control. See also for a vehicle DMSO control on cell death. Data shown are the mean ± S.E.M of three independent experiments.

Journal: PLoS ONE

Article Title: Mir-34a Mimics Are Potential Therapeutic Agents for p53-Mutated and Chemo-Resistant Brain Tumour Cells

doi: 10.1371/journal.pone.0108514

Figure Lengend Snippet: ( A, B ) D283-MED, MHH-Med1 and MEB-Med8A cells were treated with [20 µM] etoposide for indicated time points and levels of miR-34a (A) and Mdm2 mRNA ( B ) were assessed by real time qPCR. Results were normalised to cyclophilin A and fold changes relative to the untreated control. See also for a DMSO control. ( C ) D283-MED cells were transfected with siRNA directed to p53 or with non-specific siRNA as a negative control for 48 hours prior to etoposide treatment. The levels of miR-34a were assessed by qPCR as in (A). Data shown are the mean ± S.E.M of three independent experiments. (A–C) Kruskal-Wallis ANOVA test was performed (*indicates p<0.05). ( D – F ) Cell viability of D283-MED, MHH-Med1 and MEB-Med8A was measured by MTS assay upon treatment at indicated time points. ( D ) Etoposide [20 µM] ( E ) cisplatin [5 µM] ( F ) methrotrexate [5 µM]. The percentages of viable cells were relative to the untreated control. See also for a vehicle DMSO control on cell death. Data shown are the mean ± S.E.M of three independent experiments.

Article Snippet: Cisplatin (cat# 440-040) and metothrexate (cat# 440-045) were from Enzo Life Sciences UK Ltd (Exeter, UK).

Techniques: Transfection, Negative Control, MTS Assay